Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism

Hypertension

Volumn 50, Issue 5, 2007, Pages 911-918

  Catena, Cristiana ^a   Colussi, Gianluca ^a   Lapenna, Roberta ^a   Nadalini, Elisa ^a   Chiuch, Alessandra ^a   Gianfagna, Pasquale ^a   Sechi, Leonardo A ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Adrenalectomy; Diastolic filling; Echocardiography; Left ventricular hypertrophy; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE; MINERALOCORTICOID RECEPTOR; POTASSIUM; RENIN;

ADRENALECTOMY; ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTROPHY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SYSTOLE; ADENOMA; ADRENAL TUMOR; BLOOD; DRUG ANTAGONISM; HYPERALDOSTERONISM; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TIME;

ADENOMA; ADRENAL GLAND NEOPLASMS; ADRENALECTOMY; ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; POTASSIUM; PROSPECTIVE STUDIES; RECEPTORS, MINERALOCORTICOID; RENIN; SPIRONOLACTONE; TIME;

EID: 35848931662     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.095448     Document Type: Article

References (48)

1. Freel EM, Connell JM. Mechanisms of hypertension: the expanding role of aldosterone. J Am Soc Nephrol. 2004;15:1993-2001.
2. Rossi GP, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab. 2005;16:104-107.
3. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci. 2002;970:89-100.
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
5. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. (Correction. 2003;348:2271).
6. Plouin PF, Amar L, Chatellier G; for the COMETE-Conn Study Group. Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrol Dial Transplant. 2004;19:774-777.
7. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045-1050.
8. Janota T, Hradec J, Kral J. Heart in adrenal disease. Cor Vasa. 1992;34:115-122.
9. Denolle T, Chatellier G, Julien J, Battaglia C, Luo P, Plouin PF. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. Am J Hypertens. 1993;6:907-913.
10. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996;27:1039-1045.
11. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation. 1997;95:1471-1478.
12. Shigematsu Y, Mareomi H, Hideki O, Hara Y, Hayashi Y, Kodama K, Katsuhiko K, Hiwada K. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension. 1997;29:723-727.
13. Tanabe A, Naruse M, Naruse K, Hase M, Yoshimoto T, Tanaka M, Seki T, Demura R, Demura H. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res. 1997;20:85-90.
14. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bestini A, Giorni D, Scognamiglio R, Mariani M, Pessina AC. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension. 2002;40:23-27.
15. Matsumura K, Fujii K, Oniki H, Oka M, Iida M. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens. 2006;19:13-18.
16. Suzuki T, Abe H, Nagata S, Saitoh F, Iwata S, Ashizawa A, Kuramochi M, Omae T. Left ventricular structural characteristics in unilateral renovascular hypertension and primary aldosteronism. Am J Cardiol. 1988;62:1224-1227.
17. Yoshihara F, Nishikimi T, Yoshitomi Y, Nakasone I, Abe H, Matsuoka H, Omae T. Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension. Am J Hypertens. 1996;9:523-528.
18. Yoshitomi Y, Nishikimi T, Abe H, Yoshimar F, Suzuki T, Ashizawa A, Nagata S, Kuramochi M, Matsuoka H, Omae T. Comparison of changes in cardiac structure after treatment in secondary hypertension. Hypertension. 1996;27:319-323.
19. Rizzoni D, Muiesan ML, Porteri E, Salvetti M, Castellano M, Bettoni G, Tiberio G, Giulini SM, Monteduro C, Garavelli G, Agabiti-Rosei E. Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol. 1998;32:985-992.
20. Goldkorn R, Yurenev A, Blumenfeld J, Fishman D, Devereux RB. Echocardiographic comparison of left ventricular structure and function in hypertensive patients with primary aldosteronism and essential hypertension. Am J Hypertens. 2002;15:340-345.
21. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006;295:2638-2645.
22. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Novello M, Favret G, Melis A, Cavarape A, Sechi LA. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab. 2006;91:3457-3463.
23. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
24. Ferrari P, Shaw SG, Nicod J, Saner E, Nussberger J. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens. 2004;22:377-381.
25. Kem DC, Weinberger MH, Mayes DM, Nugent CA. Saline suppression of plasma aldosterone in hypertension. Arch Intern Med. 1971;128:380-386.
26. Grim CE, Weinberger MH, Higgins JT, Kramer NJ. Diagnosis of secondary forms of hypertension. A comprehensive protocol. JAMA. 1977;237:1331-1335.
27. Sahn DJ, DeMaria A, Kisslo J, Weyman A. The committee on M-mode standardization of the American Society of Echocardiography: recommendations regarding quantitation in M-mode echocardiography. Results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
28. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and geometric remodeling in arterial hypertension. J Am Coll Cardiol. 1992;19:1550-1558.
29. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
30. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and of the impact of overweight. J Am Coll Cardiol. 1992;20:1251-1260.
31. Devereux RB, Roman MJ. Evaluation of cardiac and vascular structure by echocardiography and other noninvasive techniques. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, Treatment. 2nd ed. New York, NY: Raven Press; 1995:1969-1985.
32. Reichek N, Wilson J, St John Sutton M, Piappert PA, Goidberg S, Hirshfeld JW. Noninvasive determination of left ventricular end-systolic stress: validation of the method and initial application. Circulation. 1982;65:99-109.
33. Gaasch WH, Zile MR, Hosino PK, Apstein CS, Blaustein AS. Stress-shortening relations and myocardial blood flow in compensated and failing canine hearts with pressure-overload hypertrophy. Circulation. 1989;79:872-883.
34. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, Laragh JH. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol. 1994;23:1444-1451.
35. Devereux RB, de Simone G, Pickering TG, Schwartz JE, Roman MJ. Relation of left ventricular midwall function to cardiovascular risk factors and arterial structure and function. Hypertension. 1998;31:929-936.
36. Quinones MA, Otto C, Stoddard M, Waggoner A, Zoghbi W. Recommendations for quantifications of Doppler echocardiography: a report from the Doppler quantification Task Force for the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002;15:167-184.
37. Morgan HE, Baker KM. Cardiac hypertrophy: mechanical, neural, and endocrine dependence. Circulation. 1991;83:13-25.
38. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, Laragh JH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986;105:173-176.
39. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248.
40. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11-α-hydroxysteroid dehydrogenase in the human heart. Circulation. 1995;92:175-182.
41. Schmidt BMW, Schmieder RE. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens. 2003;16:80-86.
42. Kometiani P, Gnudi L, Kahn BB, Askari A, Xie Z. Multiple signal transduction pathways link Na/K-ATPase to growth-related genes in cardiac myocytes. The role of Ras and mitogen-activated protein kinases. J Biol Chem. 1998;273:15249-15256.
43. Funder J. Mineralocorticoids and cardiac fibrosis: the decade in review. Clin Exp Pharmacol Physiol. 2001;28:1002-1006.
44. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831-1838.
45. Devereux RB. Therapeutic options in minimizing left ventricular hypertrophy. Am Heart J. 2000;139:S9-S14.
46. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, Pessina A, Porcellati C, Rappelli A, Salvetti A, Trimarco B. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation. 1997;95:1464-1470.
47. Ceruti M, Petramala L, Cotesta D, Cerci S, Serra V, Caliumi C, Iorio M, De Toma G, Ciardi A, Vitolo D, Letizia C. Ambulatory blood pressure monitoring in secondary arterial hypertension due to adrenal diseases. J Clin Hypertens. 2006;8:642-648.
48. El-Gharbawy AH, Nadig VS, Kotchen JM, Grim CE, Sagar KB, Kaldunski M, Hamet P, Pausova Z, Gaudet D, Gossard F, Kotchen TA. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension. 2001;37:845-850.